Edwards Lifesciences reported fourth‑quarter 2025 revenue of $1.57 billion, up 11.6% year‑over‑year, and adjusted earnings per share of $0.58, a miss of $0.04 against the $0.62 consensus estimate. The revenue beat was driven by a 12.0% increase in transcatheter aortic valve replacement (TAVR) sales to $1.16 billion and a more than 40% jump in transcatheter mitral and tricuspid therapies (TMTT) to $156 million. The EPS miss was largely attributable to higher patient‑access spending and a higher‑than‑expected tax rate, as CFO Scott Ullem explained, while the company maintained strong pricing power in its core TAVR segment.
The TAVR segment accounted for 74% of quarterly revenue, reflecting continued demand for the SAPIEN platform and share gains in the structural‑heart market. TMTT sales grew 40% to $156 million, driven by the launch of the SAPIEN M3 replacement valve and expanding adoption of the PASCAL and EVOQUE systems. Surgical sales were $244 million, a modest increase that was partially offset by inventory adjustments in one country. The company’s gross profit margin contracted to 78.1% from 78.9% year‑over‑year, a shift driven by foreign‑exchange headwinds and investment in new TMTT therapies, including additional manufacturing expenses related to the FAST expansion of new products.
Full‑year 2025 results showed global sales of $4.5 billion, up 10.7% on a constant‑currency basis (the correct figure, replacing the erroneous 8.6% in the original article). Adjusted EPS for the year was $2.90 to $3.05, and the company reaffirmed its 2026 outlook, projecting sales of $6.553 billion to $6.674 billion and adjusted EPS of $2.90 to $3.05. The guidance represents a slight tightening of the upper end of the previous range, reflecting the company’s confidence in sustained demand for its TAVR and TMTT portfolios.
Management highlighted that the Q4 performance was driven by strong demand for the SAPIEN M3 and the scaling of EVOQUE, while the upcoming introduction of next‑generation PASCAL in Q4 2026 and the U.S. tricuspid PASCAL launch are expected to further accelerate growth. CEO Bernard Zovighian emphasized that the company’s focus on structural heart, combined with its deep expertise and evidence base, positions it for sustainable growth and expanded profitability. CFO Ullem noted that the EPS miss was intentional, as the company invested in patient‑access initiatives to broaden market reach and manage tax exposure.
Analysts noted the EPS miss as a deliberate investment in growth, with some viewing the higher patient‑access spending and tax rate as a strategic trade‑off. The company’s guidance, coupled with its strong segment performance and management confidence, suggests a positive trajectory for the structural‑heart market, while the margin compression signals short‑term headwinds that the company expects to manage through scale and pricing power.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.